Prostate Cell News Volume 5.46 | Dec 5 2014

MicroRNA-34a Regulates WNT/TCF7 Signaling and Inhibits Bone Metastasis in Ras-Activated Prostate Cancer
Ectopic miR-34a expression inhibited bone metastasis and reduced cancer cell proliferation in a Ras-dependent xenograft model. Researchers demonstrate that miR-34a can directly interfere with the gene expression of the anti-proliferative BIRC5, by targeting BIRC5 3’UTR. [Oncotarget] Full Article

Antibody Targeting of HER2/HER3 Signaling Overcomes Heregulin-Induced Resistance to PI3K Inhibition in Prostate Cancer
Researchers found that the growth inhibitory effect of GDC-0941, a class I phosphoinositide 3-kinase (PI3K) inhibitor, is markedly reduced in the presence of heregulin. This effect was more pronounced in cells lacking PTEN function. [Int J Cancer] Abstract

BCAS2 Promotes Prostate Cancer Cells Proliferation by Enhancing AR mRNA Transcription and Protein Stability
Androgen receptor (AR) transcriptional activity and LNCaP cell growth were assessed by luciferase assay and MTT assay, respectively. Breast carcinoma amplified sequence 2 (BCAS2) expression was significantly increased in prostate cancer. [Br J Cancer] Full Article

TLR3 Engagement Induces IRF-3-Dependent Apoptosis in Androgen-Sensitive Prostate Cancer Cells and Inhibits Tumor Growth In Vivo
Scientists show that interferon regulatory factor-3 signaling plays an essential role in toll-like receptor (TLR)3-mediated apoptosis in LNCaP cells through the activation of the intrinsic and extrinsic apoptotic pathways.
[J Cell Mol Med] Full Article

The Glycosyltransferase LARGE2 Is Repressed by Snail and ZEB1 in Prostate Cancer
Researchers show that alpha-dystroglycan (αDG) hypoglycosylation is associated with epithelial-to-mesenchymal transition-like status. They examined immunoreactivity for both functionally-glycosylated αDG and E-cadherin by flow cytometry and the relative expression of ZEB1 mRNA and the αDG glycosyltransferase LARGE2 mRNA in prostate and other cancer cell lines by quantitative RT-PCR. [Cancer Biol Ther] Abstract

Minor Valepotriates from Valeriana jatamansi and Their Cytotoxicity against Metastatic Prostate Cancer Cells
Ten new valepotriates, jatamanvaltrates P-Y and a known one, nardostachin, have been isolated from the whole plants of Valeriana jatamansi. The isolated compounds were evaluated for cytotoxic activity against PC-3M cells. [Planta Med] Abstract

Trichostatin A, a Histone Deacetylase Inhibitor, Reverses Epithelial-Mesenchymal Transition in Colorectal Cancer SW480 and Prostate Cancer PC3 Cells
Scientists report the reversal effects of trichostatin A (TSA) on epithelial-mesenchymal transition and investigated the possible involved molecular mechanisms in SW480 and PC3 cells. [Biochem Biophys Res Commun] Abstract

Synergistic Effect of Curcumin on Epigallocatechin Gallate-Induced Anticancer Action in PC3 Prostate Cancer Cells
Researchers verified the combined beneficial anticancer effects of curcumin and epigallocatechin gallate on PC3 prostate cancer cells, which are resistant to chemotherapy drugs and apoptosis inducers. [BMB Rep] Abstract | Download Full Article

CLINICAL RESEARCH

A Phase II Study of Sulforaphane-Rich Broccoli Sprout Extracts in Men with Recurrent Prostate Cancer
The authors demonstrate that sulforaphane inhibits AR signaling in prostate cancer cells. They report results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer. [Invest New Drugs] Abstract

The Clinical Significance of Persistent Cancer Cells on Prostate Biopsy after High Dose-Rate Brachytherapy Boost for Intermediate-Risk Prostate Cancer
Researchers evaluated the association between post-treatment biopsy results and the probability of biochemical disease-free survival. Two sequential prospective clinical trials were undertaken in men with intermediate-risk prostate cancer. [Brachytherapy] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

XTANDI™ (Enzalutamide) Now Approved in Europe for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve
Enzalutamide is now approved in Europe for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. [Astellas Pharma Europe Ltd.] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Research Technologist – Media Development (STEMCELL Technologies Inc.)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Position – Prostate Cancer (Roswell Park Cancer Institute)

Postdoctoral Position – Prostate Cancer and Prostatic Diseases (Louisiana State University)

Postdoctoral Associate – Biomarkers Associated with Prostate Cancer (Duke Molecular Physiology Institute)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.